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cases in Nepal has come down. Due to incentive given in India, the
number of cases reporting to PHC is more than previous year.
http://dx.doi.org/10.1016/j.ijid.2012.05.12952 15th ICID Abstracts / International Journ
nactivated EV71, alum-formulated vaccine, developed to prevent
FMD caused by EV71. This study evaluated INV21 in a Phase I
linical trial in healthy adults.
Methods: Thirty-six healthy males and females aged 21 to 45
ears were enrolled into a randomised, double-blind, placebo-
ontrolled study at the Investigational Medicine Unit, National
niversity Hospital, Singapore. Subjects were enrolled to either
ow Dose [12 on INV21 (0.6 g EV71/dose); 6 on placebo] or High
ose [12 on INV21 (3g EV71/dose); 6 on placebo] group. Subjects
eceived two injections (Day 0, Day 28) intramuscularly, and were
ollowed for safety and immunogenicity assessments through Day
96.
Results: Thirty-ﬁve/36 subjects completed the study through
ay 56. Most common adverse events in INV21 and placebo sub-
ects (cough: 5/36 subjects; rhinorrhea: 5/36 subjects; pyrexia:
/36 subjects; inﬂuenza: 3/36 subjects) were mild and time-
esolved. Minimal reactions were observed at the injection site,
ith similar proﬁles seen at both dose levels. Mild (Grade 1) pain,
enderness and pruritis were reported in 1 subject in each treat-
ent group. Grade 1 erythema and induration were reported in
subject in High Dose group. No clinically signiﬁcant changes in
hemistry, haematology and urinalysis parameters were observed
n either group. Highest EV71-neutralising antibody titres were
etected 2 weeks post second dose (Day 42), with all subjects sero-
onverting (≥ 4-fold rise in titre compared to baseline) at this time
oint (Low Dose GMT = 323; High Dose GMT = 452).
Conclusion: This trial demonstrated that INV21 is a safe and
mmunogenicvaccinecandidate for thepreventionofHFMDcaused
y EV71. Future clinical trials are needed to address the ongoing
egional HFMD epidemic, and reduce mortality and morbidity.
ttp://dx.doi.org/10.1016/j.ijid.2012.05.127
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inding a cure for HIV: The need for science, collaboration and
dvocacy
. Lewin
Monash University, Melbourne, Australia
Combination antiretroviral therapy (cART) has led to a major
eduction in HIV-related mortality and morbidity but HIV can still
ot be cured. With increasing numbers of infected people, emerg-
ng new toxicities secondary to cART and the need for life-long
reatment, there is now a real urgency to ﬁnd a cure for HIV.
Thereare currentlymultiplebarriers to curingHIV. Themost sig-
iﬁcant barrier is the establishment of a latent or “silent” infection
n resting CD4+ T cells. In latent HIV infection, the virus is able to
ntegrate into the host cell genome, but does not proceed to active
eplication. Reactivation of latently infected resting CD4+ T cells
an then re-establish infection once cART is stopped. Other signif-
cant barriers to cure include residual viral replication in patients
eceiving cART. In addition, HIV can be sequestered in long lived
ells such as macrophages and astrocytes in anatomical reservoirs,
uch as the brain, gastrointestinal tract and lymphoid tissue.
Achieving either a functional cure (long-term control of HIV
n the absence of cART) or a sterilizing cure (elimination of all
IV-infected cells) remains a major challenge. Several studies havenfectious Diseases 16S (2012) e2–e157
now demonstrated that treatment intensiﬁcation with additional
antiretrovirals (ARVs) appears to have little impact on latent reser-
voirs. One potential approach to eliminate latently infected cells is
to promote viral production in these cells. If this is done in a patient
cART, subsequent rounds of viral replication will be inhibited and
the infected cell will die.
Drugs such as histone deacetylase inhibitors and methylation
inhibitors; cytokines such as IL-7; or other activating agents includ-
ing prostratin and anti-PD-1, show promising results in reversing
latency in vitro when used either alone or in combination. In addi-
tion, gene therapy has been shown to effectively reduce expression
of the HIV co-receptor CCR5 in both animal models and ex vivo
human studies. Clinical trials using some of these approaches are
currently underway.
Recent new initiatives to fund collaborative private-public part-
nerships, enhance community engagement and deﬁne a scientiﬁc
road map for cure research are likely to signiﬁcantly accelerate
advances in the elusive path to ﬁnding a cure.
http://dx.doi.org/10.1016/j.ijid.2012.05.128
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Elimination of Kala-azar: Where do we stand in 2011?
S. Bhattacharya
SEARO/WHO, New Dehli, India
Visceral Leishmaniasis or commonly known as Kala-azar is
characterized by continued fever, loss of weight, anaemia and
splenomegaly. The disease is endemic in Bangladesh (45 districts),
India (52 districts) and Nepal (12 districts). Recently, a small focus
of Kala-azar has been reported from several districts of Bhutan.
Because of the unique epidemiology (man is the only reservoir,
Phelobotomous argentepis sand ﬂy is the only vector), IRS is effective
as vector control and oral drug Miltefosine is available. Elimina-
tion is possible in the three countries where the disease is conﬁned
in limited areas. Recently, Single injection of Lipid amphotericin B
(AmBisome) has been shown effective in 95% of cases and recom-
mended as the ﬁrst line of drug.
Since the elimination started in 2005, in the three countriesMil-
tefosine and Indoor Residual spray are available. Early diagnosis
with rK39 and treatment with Miltefosine are being done. In 2010-
11, it has beenbrought to attention that compliancewith treatment
with Miltefosine is not as expected. The feasibility of implement-
ing AmBisome at the PHC level is being explored. The number of
